JAMP PHARMA Trademark

Trademark Overview


On Wednesday, September 27, 2023, a trademark application was filed for JAMP PHARMA with the United States Patent and Trademark Office. The USPTO has given the JAMP PHARMA trademark a serial number of 79390054. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, October 1, 2024. This trademark is owned by JAMP PHARMA CORPORATION. The JAMP PHARMA trademark is filed in the Pharmaceutical Products, Advertising and Business and Retail Services categories with the following description:

Pharmaceutical preparations, namely, prescription and non-prescription pharmaceutical preparations and drugs for the treatment of respiratory system diseases and disorders, cardiovascular diseases, central nervous system diseases and disorders, namely, brain diseases, spinal cord diseases and injuries, movement and seizure disorders, genitourinary diseases and disorders, namely, pelvic diseases, urological diseases and sexually transmitted diseases, gynecological diseases and disorders, gastrointestinal diseases and disorders, musculoskeletal system diseases and disorders, namely, connective tissue diseases, bone diseases, back pain, fractures, sprains, cartilage injuries, endocrine and metabolic diseases and disorders, namely, hyperlipidemia, hypercalcemia, diabetes, gout, anemia, cholestatic liver diseases, namely, primary biliary cirrhosis (PBC), skin diseases and disorders, namely, dermatitis and fungal diseases, ocular diseases and disorders, allergies, cold, cough, sinus diseases...

Business management with relation to strategy, marketing, production, personnel and retail sale matters of pharmaceutical preparations, drugs and biosimilar biologic drugs for promoting optimal health of the human body, namely, prescription and non-prescription pharmaceutical preparations, vitamins and nutritional supplements
jamp pharma

General Information


Serial Number79390054
Word MarkJAMP PHARMA
Filing DateWednesday, September 27, 2023
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, October 1, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, October 1, 2024

Trademark Statements


Description of MarkThe mark consists of a circular design interrupted by a curved opening near the bottom-center of the design, to the left of the stylized wording "JAMP PHARMA".
Goods and ServicesPharmaceutical preparations, namely, prescription and non-prescription pharmaceutical preparations and drugs for the treatment of respiratory system diseases and disorders, cardiovascular diseases, central nervous system diseases and disorders, namely, brain diseases, spinal cord diseases and injuries, movement and seizure disorders, genitourinary diseases and disorders, namely, pelvic diseases, urological diseases and sexually transmitted diseases, gynecological diseases and disorders, gastrointestinal diseases and disorders, musculoskeletal system diseases and disorders, namely, connective tissue diseases, bone diseases, back pain, fractures, sprains, cartilage injuries, endocrine and metabolic diseases and disorders, namely, hyperlipidemia, hypercalcemia, diabetes, gout, anemia, cholestatic liver diseases, namely, primary biliary cirrhosis (PBC), skin diseases and disorders, namely, dermatitis and fungal diseases, ocular diseases and disorders, allergies, cold, cough, sinus diseases and disorders, hypertension, sexual diseases and disorders, prostate diseases and disorders, cancer, obesity, inflammation and inflammatory diseases and disorders, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, infectious diseases and disorders, namely, respiratory infections, eye infections, topical infections, immunological diseases, namely, autoimmune diseases, immunologic deficiency syndrome, viral diseases and disorders, namely, herpes, hepatitis, acquired immune deficiency syndrome (aids), parasitic diseases, namely, malaria, parasitic infections, namely, intestinal worms, psychiatric diseases and disorders, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia and bipolar disorders, dental and oral diseases, namely, mouth diseases, esophageal diseases and toothaches, motion sickness, carpal tunnel syndrome and pain, namely, headaches, migraines, back pain, pain from burns, neuropathic pain, chronic pain associated with osteoarthritis of the knee, transplant rejection, hyperfibrinolysis, hereditary angioedema, drug abuse and biosimilar biologic drugs for the treatment of inflammatory diseases and disorders, namely, inflammatory connective tissue diseases and inflammatory bowel diseases, skin diseases and disorders, namely, psoriasis and hidradenitis suppurativa, ocular diseases and disorders, namely, inflammation of the uvea or uveal tract; natural health product preparations, namely, dietary supplements, nutritional supplements and herbal supplements for general health and well-being, namely, food supplements containing natural plant extracts, natural algae, natural algae extracts and fungus extracts, vitamins, mineral supplements, amino acids, fatty acids, dietary fibre, probiotics dietary supplements, enzyme and protein supplements in powder, capsule, tablet and liquid form, all for maintaining brain health, for neuroprotection, for improving or preserving cognition, memory and brain function; vitamins and nutritional supplements, namely, vitamins and nutritional supplements in the form of calcium, electrolyte drinks, energy bars, energy drinks, juice drinks, lecithin, minerals, vitamins for pharmaceutical, medicinal and therapeutic use
Goods and ServicesBusiness management with relation to strategy, marketing, production, personnel and retail sale matters of pharmaceutical preparations, drugs and biosimilar biologic drugs for promoting optimal health of the human body, namely, prescription and non-prescription pharmaceutical preparations, vitamins and nutritional supplements
NOT AVAILABLE"PHARMA"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, February 23, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateFriday, February 23, 2024
Primary Code035
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameJAMP PHARMA CORPORATION
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCA

Party NameJAMP PHARMA CORPORATION
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCA

Trademark Events


Event DateEvent Description
Tuesday, February 27, 2024APPLICATION FILING RECEIPT MAILED
Thursday, February 22, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, February 23, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, June 3, 2024NON-FINAL ACTION WRITTEN
Saturday, May 18, 2024ASSIGNED TO EXAMINER
Monday, June 24, 2024REFUSAL PROCESSED BY MPU
Monday, June 24, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, July 15, 2024REFUSAL PROCESSED BY IB
Friday, June 14, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, August 23, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 23, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, August 23, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, August 23, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, September 11, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 1, 2024PUBLISHED FOR OPPOSITION
Tuesday, October 1, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED